Want to see FR:ALNOV full AI Analyst Report?
ALNOV Stock Chart & Stats
€0.45
<€0.01(0.90%)
At close: 4:00 PM EDT
€0.45
<€0.01(0.90%)
Day’s Range― - ―
52-Week Range€0.29 - €1.04
Previous CloseN/A
Volume30.11K
Average Volume (3M)141.10K
Market Cap
€30.96M
Enterprise Value€17.64
Total Cash (Recent Filing)€19.14M
Total Debt (Recent Filing)€10.44M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding72,588,090
10 Day Avg. Volume69,615
30 Day Avg. Volume141,103
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)1.35
P/FCF Ratio-3.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€30.37M
Bulls Say, Bears Say
Bulls Say
High Gross Margins From PCR Product MixA 63% blended gross margin, driven by PCR/RUO kit sales and Primerdesign (>80% margin), provides durable unit economics. High product-level margins create scope to cover fixed costs as volumes scale, support reinvestment in R&D and margin resilience versus price pressure in select regions.
Recurring Consumables And Instrument Pull-throughInstrument sales (LightBench) plus follow-on consumables create recurring revenue that is sticky and higher margin over time. Platform adoption supports predictable reagent demand, improving revenue visibility and helping convert one-time instrument sales into long-term consumable streams and margin sustainability.
Earnings‑accretive Acquisition Expands Revenue And FootprintThe Southern Cross acquisition immediately adds meaningful revenue and geographic reach, diversifying the mix and providing scale benefits. Integration ~75% complete, and the deal is described as earnings‑accretive, supporting management’s plan to accelerate top‑line growth and move toward EBITDA breakeven.
Bears Say
Limited Liquidity And Ongoing Cash BurnNegative operating and free cash flow coupled with a low cash balance creates a tangible financing constraint. At ~£825k monthly burn and £11m cash, the company’s runway is limited absent forecasted revenue delivery or new funding, elevating dilution or operational cutback risk over the next 6–12 months.
Structural Multi‑year UnprofitabilitySustained operating losses indicate the current revenue base and cost structure do not yet support sustained profitability. Continued negative EBITDA reduces retained earnings, undermines capital generation, and forces reliance on external financing or successful scaling initiatives to achieve durable profit conversion.
Material Impairments And Weakening Balance SheetLarge non‑cash impairments and declining equity signal that past acquisitions or assets underperformed versus expectations. This weakens the balance sheet, can reduce borrowing capacity, and raises the risk of further write‑downs if revenue or margin recovery stalls, constraining long‑term financial flexibility.
Novacyt News
ALNOV FAQ
What was Novacyt’s price range in the past 12 months?
Novacyt lowest stock price was €0.29 and its highest was €1.04 in the past 12 months.
What is Novacyt’s market cap?
Novacyt’s market cap is €30.96M.
When is Novacyt’s upcoming earnings report date?
Novacyt’s upcoming earnings report date is Sep 24, 2026 which is in 53 days.
How were Novacyt’s earnings last quarter?
Novacyt released its earnings results on Apr 30, 2026. The company reported -€0.269 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Novacyt overvalued?
According to Wall Street analysts Novacyt’s price is currently Overvalued.
Does Novacyt pay dividends?
Novacyt does not currently pay dividends.
What is Novacyt’s EPS estimate?
Novacyt’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novacyt have?
Novacyt has 72,588,090 shares outstanding.
What happened to Novacyt’s price movement after its last earnings report?
Novacyt reported an EPS of -€0.269 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.514%.
Which hedge fund is a major shareholder of Novacyt?
Currently, no hedge funds are holding shares in FR:ALNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novacyt
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercialization. These vital diagnostic tools are employed in the detection of both cancer and a variety of infectious diseases. The company boasts an extensive international reach, serving markets throughout the United Kingdom, wider Europe, the United States, the Asia Pacific region, the Middle East, and Africa. Novacyt's operations are structured around three core segments. Primer Design specializes in the creation, production, and sale of molecular real-time qPCR testing devices and reagents, primarily for infectious disease diagnostics. Lab21 Products focuses on developing, manufacturing, and distributing a diverse portfolio of protein-based in-vitro diagnostic (IVD) products, also targeting infectious diseases. The IT-IS International segment is dedicated to engineering and fabricating PCR instruments used in the life sciences and food testing industries. The company's clientele principally includes hospitals and various corporate organizations.
ALNOV Company Deck
ALNOV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.View all FR:ALNOV earnings summariesTechnical Analysis
MAUNA KEA TECHNOLOGIES
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―